Can Prolaris test accurately predict risk for prostate cancer-specific mortality?

Data to be presented at the upcoming meeting of the American Society of Clinical Oncology addresses the potential of the Prolaris™ test (developed by Myriad Genetics, Inc.) to predict which men being followed under an active surveillance protocol are at greatest risk of dying from prostate cancer at 10 years of follow-up. According to the […]Image may be NSFW.
Clik here to view.